N-methyl-1H-1,3-benzodiazol-4-amine | 1504941-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-methyl-1H-1,3-benzodiazol-4-amine
• 英文别名: N-methyl-1H-benzimidazol-4-amine
• CAS: 1504941-39-2
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: UZISZGOHRVXCLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES<br/>[FR] COMPOSÉS DE LIAISON À CDK2 COVALENTS UTILISÉS À DES FINS THÉRAPEUTIQUES
  申请人：UMBRA THERAPEUTICS INC

  公开号：WO2022187693A1

  公开（公告）日：2022-09-09

  Heteroaryl sulfonyl compounds and compositions that have a CDK2 Recognition Moiety bound to an electrophile for the selective covalent modification of CDK2 to treat CDK2-mediated disorders are described.

  本文描述了具有CDK2识别基团结合到亲电体的杂环磺酰化合物和组合物，用于选择性共价修饰CDK2以治疗CDK2介导的疾病。
• [EN] OXYGEN-SUBSTITUTED SIX-MEMBERED RING PYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF<br/>[FR] COMPOSÉ DE PYRIMIDINE CYCLIQUE À SIX CHAÎNONS SUBSTITUÉ PAR OXYGÈNE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION MÉDICALE<br/>[ZH] 氧代六元环并嘧啶类化合物，其制法与医药上的用途
  申请人：GENFLEET THERAPEUTICS SHANGHAI INC

  公开号：WO2021031952A1

  公开（公告）日：2021-02-25

  提供一种对KRAS 基因突变具有选择抑制作用的氧代六元环并嘧啶类化合物及其药学上可接受的盐、立体异构体、溶剂化合物或前药，如式(I)所示，式中各基团或符号的定义详见说明书。此外，还提供包含该化合物的药物组合物，及其在制备癌症药物中的应用。
• [EN] HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'HISTONE DÉMÉTHYLASE 5 ET UTILISATIONS CORRESPONDANTES
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2020033377A1

  公开（公告）日：2020-02-13

  Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds or compositions disclosed herein for treating and/or preventing proliferative diseases, cancers, carcinoma lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer, leukemia, sarcoma and/or cardiovascular diseases in a subject in need thereof. In certain embodiments, the sarcoma is Ewing's sarcoma. Provided are methods of inhibiting a histone demethylase in a subject and/or in a cell, tissue, or biological sample. In certain embodiments, the histone demethylase is a KDM. In certain embodiments, the KDM is KDM5. In certain embodiments, the biological sample is a cell. In certain embodiments, the biological sample is a tissue.
• WO2022272133A2
  申请人：——

  公开号：WO2022272133A2

  公开（公告）日：2022-12-29